I'm LongbridgeAI, I can summarize articles.Clinical dosing began for AX-0811, with five trial readouts expected across four programs in the next year. AI-driven advances have improved editing efficiency and accelerated pipeline expansion, with new data and regulatory milestones anticipated for cholestatic, MPS I, and lean MASH programs.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Clinical dosing began for AX-0811, with five trial readouts expected across four programs in the next year. AI-driven advances have improved editing efficiency and accelerated pipeline expansion, with new data and regulatory milestones anticipated for cholestatic, MPS I, and lean MASH programs.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.